APO Research
Talk to an analyst

APO RESEARCH · REPORT

FGF-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global FGF-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchFGF-2 Inhibitors Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal FGF-2 Inhibitors Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FGF-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FGF-2 Inhibitors Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal FGF-2 Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global FGF-2 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for FGF-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of FGF-2 Inhibitors include Advenchen Laboratories, ArQule, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International and Eddingpharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global FGF-2 Inhibitors market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FGF-2 Inhibitors and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FGF-2 Inhibitors revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the FGF-2 Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

FGF-2 Inhibitors Segment by Company

Advenchen Laboratories

ArQule

AVEO Pharmaceuticals

Batu Biologics

Boehringer Ingelheim

Bristol-Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eli Lilly and Company

Hutchison MediPharma

Principia Biopharma

Santa Cruz Biotechnology

Vichem Chemie Research

AstraZeneca

Amgen

Novartis

Eisai

FGF-2 Inhibitors Segment by Type

EDP-317

Debio-1347

CPL-043

BAY-1163877

AZD-4547

ASP-5878

Others

FGF-2 Inhibitors Segment by Application

Clinic

Hospital

Others

FGF-2 Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FGF-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FGF-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FGF-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of FGF-2 Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FGF-2 Inhibitors industry.

Chapter 3: Detailed analysis of FGF-2 Inhibitors companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, FGF-2 Inhibitorsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global FGF-2 Inhibitors Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of EDP-317 Table 3. Key Players of Debio-1347 Table 4. Key Players of CPL-043 Table 3. Key Players of BAY-1163877 Table 4. Key Players of AZD-4547 Table 5. Key Players of ASP-5878 Table 6. Key Players of Others Table 7. Global FGF-2 Inhibitors Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 8. Key Players of Clinic Table 9. Key Players of Hospital Table 10. Key Players of Others Table 11. Global FGF-2 Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global FGF-2 Inhibitors Market Size by Region (2021-2026) & (US$ Million) Table 13. Global FGF-2 Inhibitors Market Share by Region (2021-2026) Table 14. Global FGF-2 Inhibitors Market Size by Region (2027-2032) & (US$ Million) Table 15. Global FGF-2 Inhibitors Market Share by Region (2027-2032) Table 16. FGF-2 Inhibitors Industry Trends Table 17. FGF-2 Inhibitors Industry Drivers Table 18. FGF-2 Inhibitors Industry Opportunities and Challenges Table 19. FGF-2 Inhibitors Industry Restraints Table 20. Global FGF-2 Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 21. Global FGF-2 Inhibitors Revenue Market Share by Company (2021-2026) Table 22. Global FGF-2 Inhibitors Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 23. Global FGF-2 Inhibitors Key Company Head Office and Area Served Table 24. Global FGF-2 Inhibitors Company, Product Type & Application Table 25. Global FGF-2 Inhibitors Company Establishment Date Table 26. Global Company Market Concentration Ratio (CR5 and HHI) Table 27. Global FGF-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 28. Global FGF-2 Inhibitors Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 30. Global FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 31. Global FGF-2 Inhibitors Revenue Market Share by Type (2021-2026) Table 32. Global FGF-2 Inhibitors Revenue Market Share by Type (2027-2032) Table 33. Global FGF-2 Inhibitors Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 35. Global FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 36. Global FGF-2 Inhibitors Revenue Market Share by Application (2021-2026) Table 37. Global FGF-2 Inhibitors Revenue Market Share by Application (2027-2032) Table 38. Advenchen Laboratories Company Information Table 39. Advenchen Laboratories Business Overview Table 40. Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Advenchen Laboratories FGF-2 Inhibitors Product Portfolio Table 42. Advenchen Laboratories Recent Development Table 43. ArQule Company Information Table 44. ArQule Business Overview Table 45. ArQule FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. ArQule FGF-2 Inhibitors Product Portfolio Table 47. ArQule Recent Development Table 48. AVEO Pharmaceuticals Company Information Table 49. AVEO Pharmaceuticals Business Overview Table 50. AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio Table 52. AVEO Pharmaceuticals Recent Development Table 53. Batu Biologics Company Information Table 54. Batu Biologics Business Overview Table 55. Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Batu Biologics FGF-2 Inhibitors Product Portfolio Table 57. Batu Biologics Recent Development Table 58. Boehringer Ingelheim Company Information Table 59. Boehringer Ingelheim Business Overview Table 60. Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio Table 62. Boehringer Ingelheim Recent Development Table 63. Bristol-Myers Squibb Company Company Information Table 64. Bristol-Myers Squibb Company Business Overview Table 65. Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio Table 67. Bristol-Myers Squibb Company Recent Development Table 68. Celon Pharma Company Information Table 69. Celon Pharma Business Overview Table 70. Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Celon Pharma FGF-2 Inhibitors Product Portfolio Table 72. Celon Pharma Recent Development Table 73. Debiopharm International Company Information Table 74. Debiopharm International Business Overview Table 75. Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Debiopharm International FGF-2 Inhibitors Product Portfolio Table 77. Debiopharm International Recent Development Table 78. Eddingpharm Company Information Table 79. Eddingpharm Business Overview Table 80. Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Eddingpharm FGF-2 Inhibitors Product Portfolio Table 82. Eddingpharm Recent Development Table 83. Eli Lilly and Company Company Information Table 84. Eli Lilly and Company Business Overview Table 85. Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Eli Lilly and Company FGF-2 Inhibitors Product Portfolio Table 87. Eli Lilly and Company Recent Development Table 88. Hutchison MediPharma Company Information Table 89. Hutchison MediPharma Business Overview Table 90. Hutchison MediPharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 91. Hutchison MediPharma FGF-2 Inhibitors Product Portfolio Table 92. Hutchison MediPharma Recent Development Table 93. Principia Biopharma Company Information Table 94. Principia Biopharma Business Overview Table 95. Principia Biopharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 96. Principia Biopharma FGF-2 Inhibitors Product Portfolio Table 97. Principia Biopharma Recent Development Table 98. Santa Cruz Biotechnology Company Information Table 99. Santa Cruz Biotechnology Business Overview Table 100. Santa Cruz Biotechnology FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 101. Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio Table 102. Santa Cruz Biotechnology Recent Development Table 103. Vichem Chemie Research Company Information Table 104. Vichem Chemie Research Business Overview Table 105. Vichem Chemie Research FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 106. Vichem Chemie Research FGF-2 Inhibitors Product Portfolio Table 107. Vichem Chemie Research Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 111. AstraZeneca FGF-2 Inhibitors Product Portfolio Table 112. AstraZeneca Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 116. Amgen FGF-2 Inhibitors Product Portfolio Table 117. Amgen Recent Development Table 118. Novartis Company Information Table 119. Novartis Business Overview Table 120. Novartis FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 121. Novartis FGF-2 Inhibitors Product Portfolio Table 122. Novartis Recent Development Table 123. Eisai Company Information Table 124. Eisai Business Overview Table 125. Eisai FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 126. Eisai FGF-2 Inhibitors Product Portfolio Table 127. Eisai Recent Development Table 128. North America FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 129. North America FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 130. North America FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 131. North America FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 132. North America FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. North America FGF-2 Inhibitors Market Size by Country (2021-2026) Table 134. North America FGF-2 Inhibitors Market Size by Country (2027-2032) Table 135. Europe FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 136. Europe FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 137. Europe FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 138. Europe FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 139. Europe FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. Europe FGF-2 Inhibitors Market Size by Country (2021-2026) Table 141. Europe FGF-2 Inhibitors Market Size by Country (2027-2032) Table 142. China FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 143. China FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 144. China FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 145. China FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 146. Asia FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 147. Asia FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 148. Asia FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 149. Asia FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 150. Asia FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Asia FGF-2 Inhibitors Market Size by Country (2021-2026) Table 152. Asia FGF-2 Inhibitors Market Size by Country (2027-2032) Table 153. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Type (2021-2026) & (US$ Million) Table 154. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Type (2027-2032) & (US$ Million) Table 155. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Application (2021-2026) & (US$ Million) Table 156. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Application (2027-2032) & (US$ Million) Table 157. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2021-2026) Table 159. South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2027-2032) Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. FGF-2 Inhibitors Product Image Figure 2. Global FGF-2 Inhibitors Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global FGF-2 Inhibitors Market Share by Type: 2025 VS 2032 Figure 4. EDP-317 Image Figure 5. Debio-1347 Image Figure 6. CPL-043 Image Figure 7. BAY-1163877 Image Figure 8. AZD-4547 Image Figure 9. ASP-5878 Image Figure 10. Others Image Figure 11. Global FGF-2 Inhibitors Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 12. Global FGF-2 Inhibitors Market Share by Application: 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Others Image Figure 16. Global FGF-2 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 18. Global FGF-2 Inhibitors Market Share by Region: 2025 VS 2032 Figure 19. Years Considered Figure 20. Global FGF-2 Inhibitors Market Share by Players in 2025 Figure 21. Global Top 5 and 10 FGF-2 Inhibitors Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global FGF-2 Inhibitors Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global FGF-2 Inhibitors Revenue Market Share by Type (2021-2032) Figure 25. Global FGF-2 Inhibitors Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global FGF-2 Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 28. North America FGF-2 Inhibitors Market Share by Type (2021-2032) Figure 29. North America FGF-2 Inhibitors Market Share by Application (2021-2032) Figure 30. North America FGF-2 Inhibitors Market Share by Country (2021-2032) Figure 31. United States FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 32. Canada FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 33. Mexico FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 34. Europe FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 35. Europe FGF-2 Inhibitors Market Share by Type (2021-2032) Figure 36. Europe FGF-2 Inhibitors Market Share by Application (2021-2032) Figure 37. Europe FGF-2 Inhibitors Market Share by Country (2021-2032) Figure 38. Germany FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 39. France FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 40. U.K. FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 41. Italy FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 42. Russia FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 43. Nordic Countries FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 44. China FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 45. China FGF-2 Inhibitors Market Share by Type (2021-2032) Figure 46. China FGF-2 Inhibitors Market Share by Application (2021-2032) Figure 47. Asia FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 48. Asia FGF-2 Inhibitors Market Share by Type (2021-2032) Figure 49. Asia FGF-2 Inhibitors Market Share by Application (2021-2032) Figure 50. Asia FGF-2 Inhibitors Market Share by Country (2021-2032) Figure 51. Japan FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 52. South Korea FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 53. Taiwan FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 54. Southeast Asia FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 55. India FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 56. Australia FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa FGF-2 Inhibitors Market Share by Type (2021-2032) Figure 59. South America, Middle East & Africa FGF-2 Inhibitors Market Share by Application (2021-2032) Figure 60. South America, Middle East & Africa FGF-2 Inhibitors Market Share by Country (2021-2032) Figure 61. Brazil FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 62. South Africa FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 63. Saudi Arabia FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 64. Turkey FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 65. Argentina FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 66. UAE FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 67. Egypt FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 68. Chile FGF-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • EDP-317
  • Debio-1347
  • CPL-043
  • BAY-1163877
  • AZD-4547
  • ASP-5878
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Advenchen Laboratories
  • ArQule
  • AVEO Pharmaceuticals
  • Batu Biologics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celon Pharma
  • Debiopharm International
  • Eddingpharm
  • Eli Lilly and Company
  • Hutchison MediPharma
  • Principia Biopharma
  • Santa Cruz Biotechnology
  • Vichem Chemie Research
  • AstraZeneca
  • Amgen
  • Novartis
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global FGF-2 Inhibitors Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 EDP-317
  5. 1.2.3 Debio-1347
  6. 1.2.4 CPL-043
  7. 1.2.5 BAY-1163877
  8. 1.2.6 AZD-4547
  9. 1.2.7 ASP-5878
  10. 1.2.8 Others
  11. 1.3 Market Analysis by Application
  12. 1.3.1 Global FGF-2 Inhibitors Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Others
  16. 1.4 Global Market Growth Prospects
  17. 1.5 Global FGF-2 Inhibitors Growth Trends by Region
  18. 1.5.1 Global FGF-2 Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  19. 1.5.2 FGF-2 Inhibitors Market Size by Region (2021-2026)
  20. 1.5.3 FGF-2 Inhibitors Market Size by Region (2027-2032)
  21. 1.6 Assumptions and Limitations
  22. 1.7 Study Goals and Objectives
  23. 1.8 Years Considered
2 Global FGF-2 Inhibitors Market Dynamics
  1. 2.1 FGF-2 Inhibitors Industry Trends
  2. 2.2 FGF-2 Inhibitors Industry Drivers
  3. 2.3 FGF-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 FGF-2 Inhibitors Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global FGF-2 Inhibitors Revenue by Company (2021-2026)
  2. 3.2 Global FGF-2 Inhibitors Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global FGF-2 Inhibitors Key Company Head office and Area Served
  4. 3.4 Global FGF-2 Inhibitors Company, Product Type & Application
  5. 3.5 Global FGF-2 Inhibitors Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global FGF-2 Inhibitors Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 FGF-2 Inhibitors Players Market Share by Revenue in 2025
  9. 3.6.3 2025 FGF-2 Inhibitors Tier 1, Tier 2, and Tier 3
4 FGF-2 Inhibitors Market by Type
  1. 4.1 Global FGF-2 Inhibitors Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global FGF-2 Inhibitors Market Size by Type (2021-2032)
  3. 4.3 Global FGF-2 Inhibitors Market Size Share by Type (2021-2032)
5 FGF-2 Inhibitors Market by Application
  1. 5.1 Global FGF-2 Inhibitors Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global FGF-2 Inhibitors Market Size by Application (2021-2032)
  3. 5.3 Global FGF-2 Inhibitors Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Advenchen Laboratories
  2. 6.1.1 Advenchen Laboratories Company Information
  3. 6.1.2 Advenchen Laboratories Business Overview
  4. 6.1.3 Advenchen Laboratories FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Advenchen Laboratories FGF-2 Inhibitors Product Portfolio
  6. 6.1.5 Advenchen Laboratories Recent Developments
  7. 6.2 ArQule
  8. 6.2.1 ArQule Company Information
  9. 6.2.2 ArQule Business Overview
  10. 6.2.3 ArQule FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 ArQule FGF-2 Inhibitors Product Portfolio
  12. 6.2.5 ArQule Recent Developments
  13. 6.3 AVEO Pharmaceuticals
  14. 6.3.1 AVEO Pharmaceuticals Company Information
  15. 6.3.2 AVEO Pharmaceuticals Business Overview
  16. 6.3.3 AVEO Pharmaceuticals FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 AVEO Pharmaceuticals FGF-2 Inhibitors Product Portfolio
  18. 6.3.5 AVEO Pharmaceuticals Recent Developments
  19. 6.4 Batu Biologics
  20. 6.4.1 Batu Biologics Company Information
  21. 6.4.2 Batu Biologics Business Overview
  22. 6.4.3 Batu Biologics FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Batu Biologics FGF-2 Inhibitors Product Portfolio
  24. 6.4.5 Batu Biologics Recent Developments
  25. 6.5 Boehringer Ingelheim
  26. 6.5.1 Boehringer Ingelheim Company Information
  27. 6.5.2 Boehringer Ingelheim Business Overview
  28. 6.5.3 Boehringer Ingelheim FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Boehringer Ingelheim FGF-2 Inhibitors Product Portfolio
  30. 6.5.5 Boehringer Ingelheim Recent Developments
  31. 6.6 Bristol-Myers Squibb Company
  32. 6.6.1 Bristol-Myers Squibb Company Company Information
  33. 6.6.2 Bristol-Myers Squibb Company Business Overview
  34. 6.6.3 Bristol-Myers Squibb Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Bristol-Myers Squibb Company FGF-2 Inhibitors Product Portfolio
  36. 6.6.5 Bristol-Myers Squibb Company Recent Developments
  37. 6.7 Celon Pharma
  38. 6.7.1 Celon Pharma Company Information
  39. 6.7.2 Celon Pharma Business Overview
  40. 6.7.3 Celon Pharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Celon Pharma FGF-2 Inhibitors Product Portfolio
  42. 6.7.5 Celon Pharma Recent Developments
  43. 6.8 Debiopharm International
  44. 6.8.1 Debiopharm International Company Information
  45. 6.8.2 Debiopharm International Business Overview
  46. 6.8.3 Debiopharm International FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Debiopharm International FGF-2 Inhibitors Product Portfolio
  48. 6.8.5 Debiopharm International Recent Developments
  49. 6.9 Eddingpharm
  50. 6.9.1 Eddingpharm Company Information
  51. 6.9.2 Eddingpharm Business Overview
  52. 6.9.3 Eddingpharm FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Eddingpharm FGF-2 Inhibitors Product Portfolio
  54. 6.9.5 Eddingpharm Recent Developments
  55. 6.10 Eli Lilly and Company
  56. 6.10.1 Eli Lilly and Company Company Information
  57. 6.10.2 Eli Lilly and Company Business Overview
  58. 6.10.3 Eli Lilly and Company FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Eli Lilly and Company FGF-2 Inhibitors Product Portfolio
  60. 6.10.5 Eli Lilly and Company Recent Developments
  61. 6.11 Hutchison MediPharma
  62. 6.11.1 Hutchison MediPharma Company Information
  63. 6.11.2 Hutchison MediPharma Business Overview
  64. 6.11.3 Hutchison MediPharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Hutchison MediPharma FGF-2 Inhibitors Product Portfolio
  66. 6.11.5 Hutchison MediPharma Recent Developments
  67. 6.12 Principia Biopharma
  68. 6.12.1 Principia Biopharma Company Information
  69. 6.12.2 Principia Biopharma Business Overview
  70. 6.12.3 Principia Biopharma FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Principia Biopharma FGF-2 Inhibitors Product Portfolio
  72. 6.12.5 Principia Biopharma Recent Developments
  73. 6.13 Santa Cruz Biotechnology
  74. 6.13.1 Santa Cruz Biotechnology Company Information
  75. 6.13.2 Santa Cruz Biotechnology Business Overview
  76. 6.13.3 Santa Cruz Biotechnology FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Santa Cruz Biotechnology FGF-2 Inhibitors Product Portfolio
  78. 6.13.5 Santa Cruz Biotechnology Recent Developments
  79. 6.14 Vichem Chemie Research
  80. 6.14.1 Vichem Chemie Research Company Information
  81. 6.14.2 Vichem Chemie Research Business Overview
  82. 6.14.3 Vichem Chemie Research FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Vichem Chemie Research FGF-2 Inhibitors Product Portfolio
  84. 6.14.5 Vichem Chemie Research Recent Developments
  85. 6.15 AstraZeneca
  86. 6.15.1 AstraZeneca Company Information
  87. 6.15.2 AstraZeneca Business Overview
  88. 6.15.3 AstraZeneca FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 AstraZeneca FGF-2 Inhibitors Product Portfolio
  90. 6.15.5 AstraZeneca Recent Developments
  91. 6.16 Amgen
  92. 6.16.1 Amgen Company Information
  93. 6.16.2 Amgen Business Overview
  94. 6.16.3 Amgen FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Amgen FGF-2 Inhibitors Product Portfolio
  96. 6.16.5 Amgen Recent Developments
  97. 6.17 Novartis
  98. 6.17.1 Novartis Company Information
  99. 6.17.2 Novartis Business Overview
  100. 6.17.3 Novartis FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Novartis FGF-2 Inhibitors Product Portfolio
  102. 6.17.5 Novartis Recent Developments
  103. 6.18 Eisai
  104. 6.18.1 Eisai Company Information
  105. 6.18.2 Eisai Business Overview
  106. 6.18.3 Eisai FGF-2 Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Eisai FGF-2 Inhibitors Product Portfolio
  108. 6.18.5 Eisai Recent Developments
7 North America
  1. 7.1 North America FGF-2 Inhibitors Market Size (2021-2032)
  2. 7.2 North America FGF-2 Inhibitors Market Size by Type
  3. 7.2.1 North America FGF-2 Inhibitors Market Size by Type (2021-2026)
  4. 7.2.2 North America FGF-2 Inhibitors Market Size by Type (2027-2032)
  5. 7.2.3 North America FGF-2 Inhibitors Market Share by Type (2021-2032)
  6. 7.3 North America FGF-2 Inhibitors Market Size by Application
  7. 7.3.1 North America FGF-2 Inhibitors Market Size by Application (2021-2026)
  8. 7.3.2 North America FGF-2 Inhibitors Market Size by Application (2027-2032)
  9. 7.3.3 North America FGF-2 Inhibitors Market Share by Application (2021-2032)
  10. 7.4 North America FGF-2 Inhibitors Market Size by Country
  11. 7.4.1 North America FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America FGF-2 Inhibitors Market Size by Country (2021-2026)
  13. 7.4.3 North America FGF-2 Inhibitors Market Size by Country (2027-2032)
  14. 7.4.4 North America FGF-2 Inhibitors Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe FGF-2 Inhibitors Market Size (2021-2032)
  2. 8.2 Europe FGF-2 Inhibitors Market Size by Type
  3. 8.2.1 Europe FGF-2 Inhibitors Market Size by Type (2021-2026)
  4. 8.2.2 Europe FGF-2 Inhibitors Market Size by Type (2027-2032)
  5. 8.2.3 Europe FGF-2 Inhibitors Market Share by Type (2021-2032)
  6. 8.3 Europe FGF-2 Inhibitors Market Size by Application
  7. 8.3.1 Europe FGF-2 Inhibitors Market Size by Application (2021-2026)
  8. 8.3.2 Europe FGF-2 Inhibitors Market Size by Application (2027-2032)
  9. 8.3.3 Europe FGF-2 Inhibitors Market Share by Application (2021-2032)
  10. 8.4 Europe FGF-2 Inhibitors Market Size by Country
  11. 8.4.1 Europe FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe FGF-2 Inhibitors Market Size by Country (2021-2026)
  13. 8.4.3 Europe FGF-2 Inhibitors Market Size by Country (2027-2032)
  14. 8.4.4 Europe FGF-2 Inhibitors Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China FGF-2 Inhibitors Market Size (2021-2032)
  2. 9.2 China FGF-2 Inhibitors Market Size by Type
  3. 9.2.1 China FGF-2 Inhibitors Market Size by Type (2021-2026)
  4. 9.2.2 China FGF-2 Inhibitors Market Size by Type (2027-2032)
  5. 9.2.3 China FGF-2 Inhibitors Market Share by Type (2021-2032)
  6. 9.3 China FGF-2 Inhibitors Market Size by Application
  7. 9.3.1 China FGF-2 Inhibitors Market Size by Application (2021-2026)
  8. 9.3.2 China FGF-2 Inhibitors Market Size by Application (2027-2032)
  9. 9.3.3 China FGF-2 Inhibitors Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia FGF-2 Inhibitors Market Size (2021-2032)
  2. 10.2 Asia FGF-2 Inhibitors Market Size by Type
  3. 10.2.1 Asia FGF-2 Inhibitors Market Size by Type (2021-2026)
  4. 10.2.2 Asia FGF-2 Inhibitors Market Size by Type (2027-2032)
  5. 10.2.3 Asia FGF-2 Inhibitors Market Share by Type (2021-2032)
  6. 10.3 Asia FGF-2 Inhibitors Market Size by Application
  7. 10.3.1 Asia FGF-2 Inhibitors Market Size by Application (2021-2026)
  8. 10.3.2 Asia FGF-2 Inhibitors Market Size by Application (2027-2032)
  9. 10.3.3 Asia FGF-2 Inhibitors Market Share by Application (2021-2032)
  10. 10.4 Asia FGF-2 Inhibitors Market Size by Country
  11. 10.4.1 Asia FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia FGF-2 Inhibitors Market Size by Country (2021-2026)
  13. 10.4.3 Asia FGF-2 Inhibitors Market Size by Country (2027-2032)
  14. 10.4.4 Asia FGF-2 Inhibitors Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa FGF-2 Inhibitors Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Type
  3. 11.2.1 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa FGF-2 Inhibitors Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Application
  7. 11.3.1 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa FGF-2 Inhibitors Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country
  11. 11.4.1 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa FGF-2 Inhibitors Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa FGF-2 Inhibitors Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst